Notice of NICHD Participation in PAR-20-036 "Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)"

Notice Number: NOT-HD-19-040

Key Dates
Release Date: November 06, 2019

Related Announcements
PAR 20-036

Issued by
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Purpose

The purpose of this Notice is to inform potential applicants that the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is participating in PAR 20-036 "Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)".

The following sections have been updated to reflect the participation of NICHD in this FOA:

Part 1. Overview Information

Components of Participating Organizations

National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Mental Health (NIMH)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.855; 93.242; 93.865

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

NICHD is particularly interested in research among adolescents and young adults, 12-24 years old, that supports:

  • Innovative strategies harnessing data-based epidemiology approaches and related technologies to improve and expedite viral suppression among hard to reach populations of adolescents and young adults who are unaware they are infected, repeatedly disengage and re-engage in care, use substances or suffer from mental illness or are unstably housed (e.g. mobile engagement strategies, virtual cohorts).
  • Improved accuracy and speed to describe the epidemiology of HIV transmission or care indicators among adolescents and young adults (testing, transmission networks, linkage to care, engagement, and suppression of viral load) at jurisdictional or national population levels
  • Data-driven epidemiology to evaluate HIV care in a timely manner among adolescents and young adults and stratified by sub-populations, such as by gender, transmission risk, race, age, or geographic region
  • Data-based epidemiology approaches to understand long-term viral suppression and the correlates and predictors of success in adolescents and young adults
  • Research to uncover novel correlates and predictors of initial and sustained HIV viral suppression capitalizing on a rich understanding of the contextual factors impacting suppression in adolescents and young adults: For example, what proportion of new cases have experienced a change in housing such as unstable housing, recently aged out of foster care or had a recent incarceration? How does stigma impact access to care and success in preventing or treating HIV? What components of syringe substitution programs (SSP)s are most successful for promoting testing and referral to HIV care?
  • Implementation science research that combines knowledge derived from epidemiology, data science and or modeling with on-the-ground experiences to improve viral suppression. Such research could focus on testing approaches to identify and diagnose hard-to-reach populations, strategies to improve service delivery, or strategies targeting barriers to service delivery and stigma. Partnerships with care implementers and community are key elements of these studies.

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Bill G. Kapogiannis, MD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-402-0698
Email: kapogiannisb@mail.nih.gov

Financial/Grants Management Contact(s)

Bryan S. Clark, MBA
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-435-6975
Email: clark1@mail.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Bill G. Kapogiannis, MD
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Telephone: 301-402-0698
Email: kapogiannisb@mail.nih.gov